ColoTest for Colon Cancer Screening Now Available at Select Walmart Locations
Reese Pharmaceutical, a privately held manufacturer of over-the-counter (OTC) branded and private label products today announced ColoTest®, its new Fecal Immunochemical Test (FIT) for colon cancer screening, is now available at 3,700 Walmart locations across the U.S. The FDA-cleared ColoTest® identifies the…
BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000
On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory (BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjiang province, China, marking a significant advance in the province’s efforts to address public health challenges. Utilizing the ‘13311i GigaLab’ technological framework, this facility supports vital life…
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results
On November 9, 2023, ImmVira announced the successful completion of Phase I clinical study conducted on late-stage patients with various tumor types for our intravenous oncolytic product, MVR-T3011 IV, in the United States. This milestone was marked by the product’s exceptional safety results…
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® (sotorasib) (960 mg or 240 mg) in combination with Vectibix® (panitumumab). Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator’s choice of…
EntroGen Receives FDA Approval for CRCdx® RAS Mutation Detection Kit as Companion Diagnostic for Vectibix®
The U.S. Food and Drug Administration (FDA) has granted approval for EntroGen’s CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix® (panitumumab), a targeted therapy used in the treatment of colorectal cancer. This landmark premarket approval (PMA) marks…
